Research progress on the structural modification and anti-lung cancer activity of natural product erianin

Published on May. 31, 2025Total Views: 189 times Total Downloads: 14 times Download Mobile

Author: LIU Jing ¹ ZHANG Na ¹ LI Xiaolu ¹  ZHAO Bin ²

Affiliation: 1. Zhongshan Torch Polytechnic, Zhongshan 528436, Guangdong Province, China 2. Guangdong Jiangmen Chinese Medicine College/Jiangmen Health Products Branch, National Engineering Research Center for Modernization of Traditional Chinese Medicine, Jiangmen 529099, Guangdong Province, China

Keywords: Erianin Structural modification Anti-lung cancer Molecular mechanisms Research progress

DOI: 10.12173/j.issn.2097-4922.202502035

Reference: LIU Jing, ZHANG Na, LI Xiaolu, ZHAO Bin. Research progress on the structural modification and anti-lung cancer activity of natural product erianin[J]. Yaoxue QianYan Zazhi, 2025, 29(5): 849-858. DOI: 10.12173/j.issn.2097-4922.202502035.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Erianin, an active constituent extracted from the orchid plant Dendrobium chrysotoxum, has demonstrated significant inhibitory effects on a variety of tumor cells. However, its clinical application is limited due to poor water solubility, low stability, and inadequate bioavailability. This article provides a review of the structural modification research of erianin, its potential to improve bioavailability and antitumor selectivity, as well as the molecular mechanism of erianin in the treatment of lung cancer, and the methods and strategies of erianin in the treatment of lung cancer are prospected, providing a basis for the application of erianin and its derivatives in the diagnosis and treatment of lung cancer, and pointing out the direction for its future drug development.

Full-text

Please download the PDF version to read the full text: download

References

1.黄小松, 余璐, 刘治坤, 等. 毛兰素抗肿瘤活性及作用机制的研究进展[J]. 浙江医学, 2024, 46(4): 444-448. [Huang XS, Yu L, Liu ZK, et al. Research progress on the antitumor activity and mechanism of action of erianin[J]. Zhejiang Medical Journal, 2024, 46(4): 444-448.] DOI: 10.12056/j.issn.1006-2785. 2024.46.4.2023-1457.

2.Ma L, Li ML, Zhang YT, et al. Recent advances of antitumor leading compound erianin: mechanisms of action and structural modification[J]. Eur J Med Chem, 2023, 261: 115844. DOI: 10.1016/j.ejmech.2023.115844.

3.李震, 曹奕鸥, 肖立俊, 等. 毛兰素及其衍生物抗肿瘤作用研究进展[J]. 中成药, 2019, 41(10): 2442-2444. [Li Z, Cao YO, Xiao LJ, et al. Research progress on the antitumor effects of erianin and its derivatives[J]. Chinese Traditional Patent Medicine, 2019, 41(10): 2442-2444.] DOI: 10.3969/j.issn1001-1528.2019.10.032.

4.Liu YZ, Hsieh MJ, Lin JT, et al. Erianin induces cell apoptosis through ERK pathway in human nasopharyngeal carcinoma[J]. Biomed Pharmacother, 2019, 111: 262-269. DOI: 10.1016/j.biopha.2019.02.090.

5.虞璐, 张怡莹, 叶佳琪, 等. 毛兰素对人肝癌细胞系HEPG2增殖、迁移、凋亡和上皮间质转化的影响及其机制[J]. 山东医药, 2023, 63(9): 17-21. [Yu L, Zhang YY, Ye JQ, et al. Effects and mechanism of erianin on the proliferation, migration, apoptosis and epithelial-mesenchymal transition of human hepatoma cell line HepG2[J]. Shandong Medical Journal, 2023, 63(9): 17-21.] DOI: 10.3969/j.issn.1002-266X.2023.09.005.

6.刘名昆. 毛兰素联合5-Fu对人胃癌细胞株MGC-803增殖凋亡的影响[D]. 湖南衡阳: 南华大学, 2016. https://cdmd.cnki.com.cn/Article/CDMD-10555-1016317518.htm.

7.Sun Y, Li G, Zhou Q, et al. Dual targeting of cell growth and phagocytosis by erianin for human colorectal cancer[J]. Drug Design Dev Ther, 2020, 14: 3301-3313. DOI: 10.2147/DDDT.S259006.

8.Li MT, He YL, Peng C, et al. Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal-regulated kinase signaling pathway[J]. Oncol Lett, 2018, 16(4): 5006-5012. DOI: 10.3892/ol.2018.9000.

9.孙婧. 铁皮石斛提取物及其活性成分毛兰素对人乳腺癌细胞抑制作用的研究[D]. 长春: 吉林大学, 2016. https://cdmd.cnki.com.cn/Article/CDMD-10183-1016083617.htm.

10.Nie H, Wang N, Huang JW, et al. Radiosynthesis and tumor microPET/CT imaging of 18F-fluoro-ethoxylerianin, an 18F-labeled erianin analogue[J]. SynOpen, 2022, 6(2): 80-85. DOI: 10.1055/a-1818-8330.

11.Wei X, Liu JJ, Xu ZM, et al. Research progress on the pharmacological mechanism, in vivo metabolism and structural modification of erianin[J]. Biomed Pharmacother, 2024, 173: 116295. DOI: 10.1016/j.biopha.2024.116295.

12.Zhao L, Zhou JJ, Huang XY, et al. Design, synthesis and anti-proliferative effects in tumor cells of new combretastatin A-4 analogs[J]. Chinese Chemical Letters, 2015, 26(8): 993-999. DOI: 10.1016/j.cclet.2015.04.019.

13.聂辉. 抗肿瘤活性毛兰素类似物的设计与合成[D]. 上海: 上海应用技术大学, 2021. https://cdmd.cnki.com.cn/Article/CDMD-10259-1022409975.htm.

14.Zhang SW, Li T, Pang W, et al. Synthesis, biological evaluation and molecular docking studies of combretastatin A-4 phosphoramidates as novel anticancer prodrugs[J]. Med Chem Res, 2020, 29(12): 2192-2202. DOI: 10.1007/s00044-020-02650-1.

15.Huang LL, Huang JW, Nie H, et al. Design, synthesis and biological evaluation of combretastatin A-4 sulfamate derivatives as potential anti-cancer agents[J]. RSC Med Chem, 2021, 12(8): 1374-1380. DOI: 10.1039/d1md00372g.

16.Lam F, Bradshaw TD, Mao H, et al. Zju-6, a novel derivative of erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities[J]. Invest New Drugs, 2012, 30(5): 1899-1907. DOI: 10.1007/s10637-011-9755-9.

17.吴范宏, 马仲林, 开振鹏, 等. 二氟甲氧基取代的二苯乙烷及反式二苯乙烯衍生物及其制备方法和应用: 中国专利, CN107311846A[P]. 2017-07-25.

18.吴范宏, 马仲林, 开振鹏, 等. 偕二氟乙基取代的二苯乙烯和二苯乙烷类衍生物及其制备方法和应用: 中国专利, ZL201710610734.5[P]. 2022-05-13.

19.Santanu M, Priyankar P. Biotin conjugated organic molecules and proteins for cancer therapy: a review[J]. Eur J Med Chem, 2018, 145: 206-223. DOI: 10.1016/j. ejmech.2018.01.001.

20.字成庭. 以鬼臼毒素、喜树碱、毛兰素为底物的靶向抗肿瘤化合物的合成及活性研究[D]. 昆明: 云南大学, 2015. https://cdmd.cnki.com.cn/Article/CDMD-10673-1015608505.htm.

21.卢静芬, 高鹏, 杨琳, 等. 毛兰素对人肺癌A549细胞迁移、侵袭、凋亡的影响及可能机制研究[J]. 现代医学, 2022, 50(8): 968-973. [Lu JF, Gao P, Yang L, et al. Effects of erianin on the migration, invasion and apoptosis of human lung cancer A549 cells and its possible mechanism[J]. Modern Medical Journal, 2022, 50(8): 968-973.] DOI: 103969/jissn1671-7562.2022.08.007.

22.邓同兴, 王敏丽, 温文静, 等. 毛兰素通过ROS/p38 MAPK通路诱导人肺癌A549细胞凋亡[J]. 中国病理生理杂志, 2019, 35(8): 1457-1462. [Deng TX, Wang ML, Wen WJ, et al. Erianin induces apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway[J]. Chinese Journal of Pathophysiology, 2019, 35 (8): 1457-1462.] DOI: 10.3969/j.issn.1000-4718.2019.08.017.

23.燕丽丽. 毛兰素抑制mTOR-S6K-CAD信号轴调控的嘧啶合成代谢抗肺癌作用的机制研究[D]. 杭州: 杭州师范大学, 2022. https://cdmd.cnki.com.cn/Article/CDMD-10346-1022836031.htm.

24.陈鹏. 石斛有效成分毛兰素抗肺癌的作用及其机制研究[D]. 上海: 上海中医药大学, 2021. https://cdmd.cnki.com.cn/Article/CDMD-10268-1024317625.htm.

25.Zhang HQ, Xie XF, Li GM, et al. Erianin inhibits human lung cancer cell growth via PI3K/Akt/mTOR pathway in vitro and in vivo[J]. Phytother Res, 2021, 35(8): 4511-4525. DOI: 10.1002/ptr.7146.

26.李胤谕. 毛兰素调节CD47/SIRPα信号轴抑制非小细胞肺癌发生发展[J]. 中国组织化学与细胞化学杂志, 2023, 32(3): 275-281. [Li YY. Erianin regulates the CD47/SIRPα signaling axis to inhibit the occurrence and development of non-small cell lung cancer[J]. Chinese Journal of Histochemistry and Cytochemistry, 2023, 32(3): 275-281.] DOI: 10.16705/j.cnki.1004-1850.2023.03.007.

27.Su C, Zhang P, Liu JW, et al. Erianin inhibits indoleamine 2,3-dioxygenase-induced tumor angiogenesis[J]. Biomed Pharmacother, 2017, 88: 521-528. DOI: 10.1016/j.biopha. 2017.01.090.

28.Lv J, Wang Z, Liu HC. Erianin suppressed lung cancer stemness and chemotherapeutic sensitivity via triggering ferroptosis[J]. Environ Toxicol, 2023, 39(2): 479-486. DOI: 10.1002/tox.23832.

29.Chen P, Wu QB, Feng J, et al. Erianin, a novel dibenzyl compound in dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis[J]. Signal Transduct Target Ther, 2020, 5(1): 51. DOI: 10.1038/s41392-020-0149-3.